STATUS: Completed

SPONSOR: Mario Negri Institute for Pharmacological Research (IRFMN)
LEAD GROUP: MaNGO
ENGOT Model: A
TITLE: NEW dosing mainTenance therapy Ovarian caNcer. A multicenter, open-label phase II trial of a new customized dosing (Rational Adjustment of Dose to reduce Adverse Reactions “RADAR” dosing) of Niraparib as maintenance therapy in platinum sensitive ovarian, fallopian tube or primary peritoneal recurrent cancer patients
ClinicalTrials.gov ID:  NCT03891576

Synopsis (click to view Italian version)

Synopsis (click to view English version)

Updates  (click to view Italian Newsletter)

MaNGO Sites (click to see the list)

STATUS: Completed. Results Published

SPONSOR: Mario Negri Institute for Pharmacological Research (IRFMN)
LEAD GROUP: MaNGO
ENGOT Model: A
TITLE: Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum
ClinicalTrials.gov ID: NCT01379989
MaNGO sites (click to see the list)

Sinossi (Italian)(click to view pdf)

Synopsis (English)(click to view pdf)

ESMO 2020 (click to view pdf)

INOVATYON (click to read the article)

STATUS: Completed. Results Published

SPONSOR: Mario Negri Institute for Pharmacological Research (IRFMN)
LEAD GROUP: MaNGO
ENGOT Model: Not Applicable
TITLE: Best Approach in Resistant-Ovarian-Cancer with-Cediranib-Olaparib. An Italian multicenter randomized phase II study of weekly paclitaxel vs. Cediranib-Olaparib with continuous schedule vs. Cediranib-Olaparib with intermittent schedule in patients with platinum resistant high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer
ClinicalTrials.gov ID: NCT03314740

Sinossi  (click to view pdf)

ESMO 2019  (click to view the abstract)

BAROCCO  (click to read the article)